CINCINNATI--(BUSINESS WIRE)--CinPhloro Pharma, a CinRx portfolio company advancing CIN-103 as a new approach for the chronic treatment of irritable bowel syndrome with predominant diarrhea (IBS-D), today announced the first clinical trial participant has been dosed in its Phase 2 enviva study. CIN-103, a novel formulation of phloroglucinol intended for long-term use, is a non-opioid based small molecule designed to address multiple IBS-D action points including motility, secretion, pain, spasms and inflammation..

辛辛那提--（商业新闻短讯）--辛普洛尔制药公司，一家辛普洛尔投资组合公司，将CIN-103作为慢性治疗腹泻型肠易激综合征（IBS-D）的新方法，今天宣布第一名临床试验参与者已在其2期enviva研究中服用。CIN-103是一种长期使用的新型间苯三酚制剂，是一种非阿片类小分子，旨在解决多种IBS-D作用点，包括运动，分泌，疼痛，痉挛和炎症。。

“IBS-D is a complex condition impacting the daily lives of more than 16 million people in the United States alone with no approved medicines for long-term treatment,” said Jon Isaacsohn, M.D., Founder and Chief Executive Officer at CinRx Pharma. “CIN-103 is an improved formulation and delivery of phloroglucinol, which is an approved product in select countries outside of the U.S.

CinRx Pharma创始人兼首席执行官Jon Isaacsohn医学博士说：“IBS-D是一种复杂的疾病，仅在美国就影响了1600多万人的日常生活，没有经过批准的长期治疗药物。”。“CIN-103是一种改进的间苯三酚配方和递送方法，是美国以外部分国家批准的产品。

for the treatment of gastrointestinal disorders. The enhanced pharmacokinetic (PK) properties of CIN-103 combine immediate-release and delayed-release processes for a proprietary pulsatile delivery offering sustained drug exposures with less frequent dosing while maintaining efficacy over time.”.

用于治疗胃肠道疾病。CIN-103的增强药代动力学（PK）特性结合了立即释放和延迟释放过程，用于专有的脉冲递送，提供持续的药物暴露，剂量较低，同时随着时间的推移保持功效。”。

“CIN-103 has great potential to address an unmet medical need for IBS-D and provide physicians and patients with an improved therapeutic option for long-term management of this multifactorial condition,” said Darren Brenner, M.D., Professor of Gastroenterology Medicine & Surgery at Northwestern University’s Feinberg School of Medicine.

西北大学范伯格医学院胃肠医学与外科教授达伦·布伦纳（DarrenBrenner）医学博士说：“CIN-103在解决IBS-D未满足的医疗需求方面具有巨大潜力，并为医生和患者长期管理这种多因素疾病提供了改进的治疗选择。”。

“I am encouraged by early studies of CIN-103 demonstrating a superior PK profile and absence of anticholinergic side effects compared to other antispasmodics like phloroglucinol. Previous investigations of antispasmodics available in the U.S. suffer from outdated data and methodological limitations.

“与间苯三酚等其他解痉药相比，CIN-103的早期研究显示出优越的PK特征和无抗胆碱能副作用，这让我感到鼓舞。美国以前对解痉药的研究存在过时的数据和方法学局限性。

Ongoing research involving CIN-103 holds promise for improving global symptoms in patients with IBS-D.”.

正在进行的涉及CIN-103的研究有望改善IBS-D患者的整体症状。”。

About the enviva Study:

关于enviva研究：

The Phase 2 enviva study (NCT06153420) is a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of multiple dose strengths of CIN-103 in adults with IBS-D over 12 weeks of treatment. The study endpoints include patients’ clinical response relative to placebo on abdominal pain and stool consistency (as a composite responder).

enviva 2期研究（NCT06153420）是一项随机，双盲，安慰剂对照研究，旨在评估多剂量强度的CIN-103在IBS-D成人治疗12周后的安全性和有效性。研究终点包括患者相对于安慰剂对腹痛和粪便稠度的临床反应（作为复合反应者）。

The trial aims to enroll 450 participants. More information can be found at www.envivastudy.com..

该试验旨在招募450名参与者。更多信息请访问www.envivastudy.com。。

About CinPhloro Pharma:

关于CinPhloro Pharma：

CinPhloro Pharma, a CinRx portfolio company, is dedicated to developing the first safe, effective and long-term treatment option for irritable bowel syndrome with predominant diarrhea (IBS-D). CinPhloro’s CIN-103 is a novel formulation of phloroglucinol, a small molecule available in certain countries for symptomatic relief of functional GI disorders.

CinPhloro Pharma是一家CinRx投资组合公司，致力于开发首个安全，有效和长期治疗腹泻型肠易激综合征（IBS-D）的选择。CinPhloro的CIN-103是间苯三酚的一种新型制剂，间苯三酚是一种小分子，在某些国家可用于缓解功能性胃肠道疾病的症状。

CIN-103 was modified to address the shortcomings of phloroglucinol, including its short half-life, and to target multiple IBS-D action points, including motility, secretion, pain, spasms and inflammation..

对CIN-103进行了修改，以解决间苯三酚的缺点，包括其半衰期短，并针对多个IBS-D作用点，包括运动，分泌，疼痛，痉挛和炎症。。

About CinRx Pharma:

关于CinRx Pharma：

CinRx Pharma is a biotech company advancing a diverse portfolio of high-impact medicines through clinical development with a unique hub-and-spoke business model. CinRx’s approach combines financing with the efficient progression of therapeutic candidates within its portfolio, each managed by CinRx’s central infrastructure and operating team.

CinRx Pharma是一家生物技术公司，通过临床开发，以独特的中心辐射商业模式推进多种高影响力药物的组合。CinRx的方法将融资与投资组合中候选治疗药物的有效进展相结合，每个候选治疗药物均由CinRx的中央基础设施和运营团队管理。

Current CinCos address areas of high unmet medical need including metabolic, gastrointestinal, and oncology. Differentiated by an asset selection process agnostic to therapeutic area, a strategic CRO partnership, and insights from thousands of development programs, CinRx identifies, funds and accelerates promising drugs with the potential to have the highest impact on patients’ quality of life.

目前的CINCO解决了高度未满足的医疗需求领域，包括代谢，胃肠道和肿瘤学。CinRx通过与治疗领域不可知的资产选择过程，战略CRO合作伙伴关系以及数千个发展计划的见解而有所不同，它可以识别，资助和加速有潜力对患者生活质量产生最大影响的有前景的药物。

CinRx Pharma is headquartered in Cincinnati, Ohio..

辛那提制药公司总部位于俄亥俄州辛辛那提。。

For more information, please visit www.CinRx.com or follow the company on X and LinkedIn.

有关更多信息，请访问www.CinRx.com或通过X和LinkedIn关注该公司。